RxDoctor Payments Data

Joe Ventimiglia

Family Medicine · North Richland Hills, TXNPI 1083647945

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novo Nordisk at 27.1% of the total. Reporting peaked in 2022 at $180 and has fallen 68.5% since, to $57 in 2024. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.

$319in general payments, 2019–2025

Across 17 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$86
  • Organon$66
  • Lilly USA, LLC$45
  • Otsuka America Pharmaceutical, Inc.$44
  • Coopersurgical, Inc.$20
  • Pfizer$20
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$319100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$319 in reported general payments places this provider in the 40th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$41,572
Medicare patients
91
Services billed
528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$146,388
XareltoRivaroxaban25$23,496
EliquisApixaban18$19,810
MounjaroTirzepatide17$17,622
Esomeprazole Magnesium11$4,702
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen78$3,706
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,515
Clonidine23$2,057
Pregabalin16$1,970
BreynaBudesonide/Formoterol Fumarate12$1,951
Quetiapine Fumarate18$1,614
Levothyroxine Sodium144$1,547
Metronidazole15$1,501
Duloxetine Hcl31$1,478
Febuxostat12$1,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$86$146,388129 claims
PfizerEliquis$20$19,81018 claims
Lilly USA, LLCMounjaro$45$17,62217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,760 family medicine providers in Texas.

Other family medicine in North Richland Hills

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →